Aptera Motors Corp. to Participate in H.C. Wainwright 28th Annual Global Investment Conference
Get Alerts SEV Hot Sheet
Join SI Premium – FREE
CARLSBAD, Calif., Sept. 10, 2026 (GLOBE NEWSWIRE) -- Aptera Motors Corp. (Nasdaq: SEV), a solar mobility company advancing the future of efficient transportation, today announced that management will participate in the H.C. Wainwright 28th Annual Global Investment Conference, taking place September 14 through 16, 2026 at the Lotte New York Palace Hotel in New York City.
Aptera management will hold one-on-one meetings with institutional investors throughout the conference. Investors interested in scheduling a meeting should contact their H.C. Wainwright representative or the conference organizers directly.
The H.C. Wainwright Global Investment Conference brings together public companies, institutional investors, family offices, and other capital markets participants for presentations, one-on-one meetings, and networking across the healthcare, technology, energy, and industrial sectors.
About Aptera Motors Corp.
Aptera Motors Corp. (Nasdaq: SEV) is a solar mobility company driven by a mission to advance the future of efficient transportation. Its flagship vehicle is conceived to be a paradigm-shifting solar electric vehicle that leverages breakthroughs in aerodynamics, material science, and solar technology to pursue new levels of efficiency. As a public benefit corporation, Aptera is committed to building a sustainable business that positively impacts its stakeholders and the environment. Aptera is headquartered in Carlsbad, California. For more information, please visit www.aptera.us.
Media Contact
[email protected]
Investor Relations
Aptera Motors Corp.
[email protected]
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Widgets & Web Launches AI-Operated Investor Relations Websites for Public Companies at a Fixed $299 per Month
- JST Buyback & Burn Upgrade: GasFree Revenue and $20.34M Surplus Injected as JUST's Ecosystem Trio Solidifies JST Token Value
- Johnson & Johnson announces ERLEADA® (apalutamide) treatment before and after surgery reduces risk of recurrence or death by 62% versus surgery alone in high-risk prostate cancer
Create E-mail Alert Related Categories
Globe Newswire, Press ReleasesRelated Entities
H.C. WainwrightSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!





Tweet
Share